Achmea Investment Management’s Royalty Pharma RPRX Stock Holding History

Achmea Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.6M	Buy	474,989 +442,307	+1,353%	+$23M	0.67%	42
2026 Q1	$1.57M	Sell	32,682 -1,511	-4%	-$66.2K	0.04%	103
2025 Q4	$1.32M	Buy	+34,193	New	+$1.3M	0.03%	113
2025 Q3	–	Sell	-34,193	Closed	-$1.23M	–	331
2025 Q2	$1.23M	Buy	+34,193	New	+$1.13M	0.02%	304
2023 Q3	–	Sell	-19,585	Closed	-$602K	–	608
2023 Q2	$602K	Hold	19,585	–	–	0.01%	475
2023 Q1	$705K	Sell	19,585 -19,585	-50%	-$726K	0.02%	426
2022 Q4	$1.45M	Buy	39,170 +19,585	+100%	+$817K	0.05%	332
2022 Q3	$787K	Buy	19,585 +19,094	+3,889%	+$816K	0.03%	429
2022 Q2	$21K	Buy	+491	New	+$20.1K	﹤0.01%	596
2021 Q4	–	Sell	-491	Closed	-$17K	–	528
2021 Q3	$17K	Buy	+491	New	+$19.1K	﹤0.01%	609
2021 Q2	–	Sell	-26,891	Closed	-$1.17M	–	509
2021 Q1	$1.17M	Buy	+26,891	New	+$1.27M	0.04%	395

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Achmea Investment Management's RPRX Position: Q2 2026 in Review

Achmea Investment Management increased its Royalty Pharma (RPRX) stake by 1,353% in Q2 2026, buying an estimated $23M and bringing the position to 474,989 shares worth $26.6M. The position accounts for 0.67% of the portfolio, ranked #42.

Achmea Investment Management first reported a position in RPRX in Q1 2021 and has held it in 11 quarters since. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Achmea Investment Management held 474,989 shares of Royalty Pharma worth $26.6M as of Q2 2026.
Achmea Investment Management bought 442,307 Royalty Pharma shares in Q2 2026, an estimated $23M.
Royalty Pharma made up 0.67% of Achmea Investment Management's portfolio in Q2 2026, its #42 holding.
Achmea Investment Management first reported a position in Royalty Pharma in Q1 2021 and has held it in 11 quarters since.
641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Achmea Investment Management's 13F filing for Q2 2026, filed 20 Jul 2026.